Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Neuroscience Bulletin
Erschienen in:

01.04.2019 | Original Article

Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina

verfasst von: Jing Guo, Shaozhou Ni, Qihang Li, Jian-Zhi Wang, Ying Yang

Erschienen in: Neuroscience Bulletin | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Hyperhomocysteinemia (Hhcy) is an independent risk factor for Alzheimer’s disease (AD). Visual dysfunction is commonly found and is positively correlated with the severity of cognitive defects in AD patients. Our previous study demonstrated that Hhcy induces memory deficits with AD-like tau and amyloid-β (Aβ) pathologies in the hippocampus, and supplementation with folate and vitamin B12 (FB) prevents the Hhcy-induced AD-like pathologies in the hippocampus. Here, we investigated whether Hhcy also induces AD-like pathologies in the retina and the effects of FB. An Hhcy rat model was produced by vena caudalis injection of homocysteine for 14 days, and the effects of FB were assessed by simultaneous supplementation with FB in drinking water. We found that Hhcy induced vessel damage with Aβ and tau pathologies in the retina, while simultaneous supplementation with FB remarkably attenuated the Hhcy-induced tau hyperphosphorylation at multiple AD-related sites and Aβ accumulation in the retina. The mechanisms involved downregulation of amyloid precursor protein (APP), presenilin-1, beta-site APP-cleaving enzyme 1, and protein phosphatase-2A. Our data suggest that the retina may serve as a window for evaluating the effects of FB on hyperhomocysteinemia-induced Alzheimer-like pathologies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007, 14: e1–26.CrossRefPubMed
2.
Wang QH, Wang X, Bu XL, Lian Y, Xiang Y, Luo HB, et al. Comorbidity burden of dementia: a hospital-based retrospective study from 2003 to 2012 in seven cities in china. Neurosci Bull 2017, 33: 703–710.CrossRefPubMedPubMedCentral
3.
4.
Mendes D, Oliveira MM, Moreira PI, Coutinho J, Nunes FM, Pereira DM, et al. Beneficial effects of white wine polyphenols-enriched diet on Alzheimer’s disease-like pathology. J Nutr Biochem 2018, 55: 165–177.CrossRefPubMed
5.
6.
Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson’s disease. Brain 2009, 132: 1128–1145.CrossRefPubMed
7.
Calabresi PA, Balcer LJ, Frohman EM. Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain 2010, 133: 1575–1577.CrossRefPubMedPubMedCentral
8.
Ong YT, De Silva DA, Cheung CY, Chang HM, Chen CP, Wong MC, et al. Microvascular structure and network in the retina of patients with ischemic stroke. Stroke 2013, 44: 2121–2127.CrossRefPubMed
9.
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011, 54 Suppl 1: S204–217.CrossRefPubMed
10.
La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol 2016, 79: 90–109.CrossRefPubMed
11.
Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer’s: exploring disease in the retina. Acta Neuropathol 2016, 132: 767–787.CrossRefPubMedPubMedCentral
12.
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002, 346: 476–483.CrossRefPubMed
13.
Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998, 55: 1449–1455.CrossRefPubMed
14.
Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010, 75: 1408–1414.CrossRefPubMed
15.
Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005, 82: 636–643.CrossRefPubMed
16.
Miller AL. The methionine-homocysteine cycle and its effects on cognitive diseases. Altern Med Rev 2003, 8: 7–19.PubMed
17.
Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002, 70: 694–702.CrossRefPubMed
18.
Kamath AF, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 2006, 107: 591–593.CrossRefPubMedPubMedCentral
19.
Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, et al. Hyperhomocysteinemic Alzheimer’s mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 2006, 22: 651–656.CrossRefPubMed
20.
Zhang CE, Wei W, Liu YH, Peng JH, Tian Q, Liu GP, et al. Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 2009, 174: 1481–1491.CrossRefPubMedPubMedCentral
21.
Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 2008, 29: 1654–1665.CrossRefPubMed
22.
Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345: 1593–1600.CrossRefPubMed
23.
Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003, 26: 137–146.CrossRefPubMed
24.
Sasaki K, Duan J, Murohara T, Ikeda H, Shintani S, Shimada T, et al. Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation. J Am Coll Cardiol 2003, 42: 364–372.CrossRef
25.
Gupta SK, Kumar B, Nag TC, Agrawal SS, Agrawal R, Agrawal P, et al. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther 2011, 27: 123–130.CrossRefPubMed
26.
27.
Brion JP, Couck AM, Conreur JL. Calcineurin (phosphatase 2B) is present in neurons containing neurofibrillary tangles and in a subset of senile plaques in Alzheimer’s disease. Neurodegeneration 1995, 4: 13–21.CrossRefPubMed
28.
Minthon L, Hesse C, Sjogren M, Englund E, Gustafson L, Blennow K. The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neurosci Lett 1997, 226: 65–67.CrossRefPubMed
29.
Takahashi M, Tsujioka Y, Yamada T, Tsuboi Y, Okada H, Yamamoto T, et al. Glycosylation of microtubule-associated protein tau in Alzheimer’s disease brain. Acta Neuropathol 1999, 97: 635–641.CrossRefPubMed
30.
Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11: 153–163.CrossRefPubMed
31.
Vincent IJ, Davies P. Phosphorylation characteristics of the A68 protein in Alzheimer’s disease. Brain Res 1990, 531: 127–135.CrossRefPubMed
32.
Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008, 85: 148–175.CrossRefPubMed
33.
Liu Y, Su Y, Wang J, Sun S, Wang T, Qiao X, et al. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int 2013, 62: 458–467.CrossRefPubMed
34.
Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain 2014, 137: 2834–2846.CrossRefPubMed
35.
Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011, 10: 698–712.CrossRefPubMed
36.
37.
Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, et al. Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011, 7: 102–111.CrossRefPubMedPubMedCentral
38.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014, 370: 311–321.CrossRefPubMed
39.
40.
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302: 2557–2564.CrossRefPubMedPubMedCentral
41.
McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998, 13: 235–239.CrossRefPubMed
42.
Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006, 580: 2994–3005.CrossRefPubMed
43.
44.
Sontag JM, Nunbhakdi-Craig V, Montgomery L, Arning E, Bottiglieri T, Sontag E. Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation. J Neurosci 2008, 28: 11477–11487.CrossRefPubMedPubMedCentral
45.
Troen AM, Shukitt-Hale B, Chao W-H, Albuquerque B, Smith DE, Selhub J, et al. The cognitive impact of nutritional homocysteinemia in Apolipoprotein-E deficient mice. J Alzheimers Dis 2006, 9: 381–392.CrossRefPubMed
46.
Ong SS, Doraiswamy PM, Lad EM. Controversies and future directions of ocular biomarkers in Alzheimer disease. JAMA Neurol 2018, 75: 650–651.CrossRefPubMed
47.
Ascaso FJ, Cruz N, Modrego PJ, Lopez-Anton R, Santabarbara J, Pascual LF, et al. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J Neurol 2014, 261: 1522–1530.CrossRefPubMed
48.
Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight 2017, 2.
49.
Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer’s and Parkinson’s disease patients. Brain Pathol 2014, 24: 25–32.CrossRefPubMed
50.
Regland B, Abrahamsson L, Gottfries CG, Magnus E. Vitamin B12 analogues, homocysteine, methylmalonic acid, and transcobalamins in the study of vitamin B12 deficiency in primary degenerative dementia. Dement Geriatr Cogn Disord 1990, 1: 272–277.CrossRef
51.
Shu XJ, Li ZF, Chang YW, Liu SY, Wang WH, Li X. Different doses of folic acid and vitamin B12 to treat rabbits with deep venous thrombosis and hyperhomocysteinemia. Exp Ther Med 2018, 15: 2874–2878.PubMedPubMedCentral
52.
Guilliams TG. Homocysteine - a risk factor for vascular diseases: guidelines for the clinical practice. JANA 2004, 7: 11–24.
Metadaten
Titel
Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina
verfasst von
Jing Guo
Shaozhou Ni
Qihang Li
Jian-Zhi Wang
Ying Yang
Publikationsdatum
01.04.2019
Verlag
Springer Singapore
Erschienen in
Neuroscience Bulletin / Ausgabe 2/2019
Print ISSN: 1673-7067
Elektronische ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-018-0293-8

Weitere Artikel der Ausgabe 2/2019

NMDA Receptor Antagonist MK801 Protects Against 1-Bromopropane-Induced Cognitive Dysfunction

  • Original Article

Kir2.1 Channel Regulation of Glycinergic Transmission Selectively Contributes to Dynamic Mechanical Allodynia in a Mouse Model of Spared Nerve Injury

  • Original Article

Comparison of Reference Genes for Transcriptional Studies in Postmortem Human Brain Tissue Under Different Conditions

  • Letter to the Editor

Altered Local Field Potential Relationship Between the Parafascicular Thalamic Nucleus and Dorsal Striatum in Hemiparkinsonian Rats

  • Open Access
  • Original Article

Parkinson’s Disease Risk Variant rs1109303 Regulates the Expression of INPP5K and CRK in Human Brain

  • Letter to the Editor

Human Brain Slice Culture: A Useful Tool to Study Brain Disorders and Potential Therapeutic Compounds

  • Review

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Erneut Hinweise für Neuroprotektion durch Gürtelroseimpfung

Ergebnisse eines kürzlich publizierten „natürlichen Experiments“ in Wales legten nahe, dass eine Herpes-Zoster-Impfung das Demenzrisiko senkt. Jetzt hat das Studienteam ähnliche Daten aus Australien publiziert, die in die gleiche Richtung zeigen. Offene Fragen bleiben allerdings so oder so.

Podcast

Leben statt zu Überleben: Post-Intensive-Care-Syndrom

Immer mehr Menschen überleben kritische Erkrankungen. Aber Beatmung, Sedierung und die Eindrücke der Intensivstation hinterlassen Spuren. Das Post-Intensive-Care-Syndrom kann die Folge sein. Es ist nicht nur eine Herausforderung für Kliniken, sondern auch Hausarztpraxen. Mit Allgemeinmediziner Prof. Dr. med. Konrad Schmidt sprechen wir in dieser Folge darüber, wie die Überlebenden wieder ins Leben finden können.

Zeitschrift für Allgemeinmedizin, DEGAM

Ehe schützt nicht vor Demenz

  • 25.04.2025
  • Demenz
  • Nachrichten

Eigentlich leben Verheiratete länger und gesünder. Eine aktuelle Untersuchung kommt jedoch zu dem überraschenden Schluss, dass sie eher an Demenz erkranken als nie Verheiratete, Geschiedene oder Verwitwete.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise